IL-6 can potentially influence anti-PD-L1 efficacy through several mechanisms, including support of cancer cell fitness,2,4 inhibition of Th1 responses,5,8,10 promotion of immunosuppressive myeloid cells,7,9,40,41,42 or disruption of conventional dendritic cells (cDCs).43 This evidence concerns the gene CD274 and cancer.